![]()
|
|
||||||||
J. Biol. Chem., Vol. 282, Issue 11, 7991-7996, March 16, 2007
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||







||1
From the
Departments of
Pharmacology, ||Biochemistry, and
Cellular & Structural Biology, University of Texas Health Science Center, San Antonio, Texas 78229 and the ¶Life Sciences Institute, University of Michigan, Ann Arbor, Michigan 48109
Adiponectin functions as an insulin sensitizer, and yet the underlying molecular mechanism(s) remains largely unknown. We found that treating C2C12 myotubes with adiponectin or rapamycin enhanced the ability of insulin to stimulate IRS-1 tyrosine phosphorylation and Akt phosphorylation, concurrently with reduced p70 S6 kinase phosphorylation at Thr389 as well as IRS-1 phosphorylation at Ser302 and Ser636/639. Overexpression of dominant-negative AMP kinase (AMPK), but not dominant-negative p38 MAPK, reduced the insulin-sensitizing effect of adiponectin. Rapamycin, but not adiponectin, enhanced insulin-stimulated Akt phosphorylation in HeLa cells, which lack LKB1, and exogenous expression of LKB1 in HeLa cells rescued the insulin-sensitizing effect of adiponectin. Finally, overexpression of wild-type Rheb (Ras homology-enriched in brain) or the TSC2 mutant lacking the AMPK phosphorylation site (TSC2S1345A) inhibited the insulin-sensitizing effect of adiponectin in C2C12 cells. These results indicate that activation of the LKB1/AMPK/TSC1/2 pathway alleviates the p70 S6 kinase-mediated negative regulation of insulin signaling, providing a mechanism by which adiponectin increases insulin sensitivity in cells.
Received for publication, January 4, 2007 , and in revised form, January 22, 2007.
* This work was supported by RO1 Grants from the National Institutes of Health (to F. L., L. Q. D., and K.-L. G.) and a Career Development Award from the American Diabetes Association (to L. Q. D.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 To whom correspondence should be addressed: Dept. of Pharmacology, University of Texas Health Science Center, 7703 Floyd Curl Dr., San Antonio, TX 78229. E-mail: liuf{at}uthscsa.edu.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
F. F. Chehab Minireview: Obesity and LipOdystrophy--Where Do the Circles Intersect? Endocrinology, March 1, 2008; 149(3): 925 - 934. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Hojlund, D. Glintborg, N. R. Andersen, J. B. Birk, J. T. Treebak, C. Frosig, H. Beck-Nielsen, and J. F.P. Wojtaszewski Impaired Insulin-Stimulated Phosphorylation of Akt and AS160 in Skeletal Muscle of Women With Polycystic Ovary Syndrome Is Reversed by Pioglitazone Treatment Diabetes, February 1, 2008; 57(2): 357 - 366. [Abstract] [Full Text] [PDF] |
||||
![]() |
D Barb, A Neuwirth, C S Mantzoros, and S P Balk Adiponectin signals in prostate cancer cells through Akt to activate the mammalian target of rapamycin pathway Endocr. Relat. Cancer, December 1, 2007; 14(4): 995 - 1005. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Sevillano, J. de Castro, C. Bocos, E. Herrera, and M. P. Ramos Role of Insulin Receptor Substrate-1 Serine 307 Phosphorylation and Adiponectin in Adipose Tissue Insulin Resistance in Late Pregnancy Endocrinology, December 1, 2007; 148(12): 5933 - 5942. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Langouche, S. Vander Perre, P. J. Wouters, A. D'Hoore, T. K. Hansen, and G. Van den Berghe Effect of Intensive Insulin Therapy on Insulin Sensitivity in the Critically Ill J. Clin. Endocrinol. Metab., October 1, 2007; 92(10): 3890 - 3897. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |